NASDAQ:ANCN

Anchiano Therapeutics Stock Forecast, Price & News

$1.57

+0.07 (+4.67 %)

(As of 11/25/2020 12:00 AM ET)

Add

Compare

Today's Range

$1.52

Now: $1.57▼

$1.79

50-Day Range

$1.09

MA: $1.26▼

$1.52

52-Week Range

$0.51

Now: $1.57▼

$2.72

Volume113,097 shs

Average Volume171,690 shs

Market Capitalization$11.65 million

P/E Ratio10.47

Dividend YieldN/A

Beta0.61

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Anchiano Therapeutics.

2.5 Community Rank

Outperform Votes
Anchiano Therapeutics has received 58 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Anchiano Therapeutics has received 60 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Anchiano Therapeutics has received 50.85% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Anchiano Therapeutics and other stocks. Vote “Outperform” if you believe ANCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Anchiano Therapeutics does not currently pay a dividend.
Dividend Growth
Anchiano Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anchiano Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.88% of the stock of Anchiano Therapeutics is held by insiders.
Percentage Held by Institutions
Only 10.98% of the stock of Anchiano Therapeutics is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Anchiano Therapeutics are expected to decrease in the coming year, from ($1.81) to ($3.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anchiano Therapeutics is 10.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.69.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anchiano Therapeutics is 10.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.75.
Price to Book Value per Share Ratio
Anchiano Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.75 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ANCN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.anchiano.com

Phone857-259-4622

Employees16

Debt

Debt-to-Equity RatioN/A

Current Ratio3.25

Quick Ratio5.52

Price-To-Earnings

Trailing P/E Ratio10.47

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.72 per share

Price / Book2.18

Profitability

EPS (Most Recent Fiscal Year)($3.46)

Net Income$-27,120,000.00

Net MarginsN/A

Return on Equity36.08%

Return on Assets27.40%

Miscellaneous

Outstanding Shares7,420,000

Market Cap$11.65 million

Next Earnings Date3/16/2021 (Estimated)

OptionableNot Optionable

$1.57

+0.07 (+4.67 %)

(As of 11/25/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

Anchiano Therapeutics (NASDAQ:ANCN) Frequently Asked Questions

How has Anchiano Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Anchiano Therapeutics' stock was trading at $0.8191 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANCN shares have increased by 91.7% and is now trading at $1.57.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Anchiano Therapeutics?

Wall Street analysts have given Anchiano Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Anchiano Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Anchiano Therapeutics' next earnings date?

Anchiano Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for Anchiano Therapeutics.

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) announced its quarterly earnings data on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.12.
View Anchiano Therapeutics' earnings history.

Are investors shorting Anchiano Therapeutics?

Anchiano Therapeutics saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 60,100 shares, an increase of 526.0% from the October 15th total of 9,600 shares. Based on an average trading volume of 444,100 shares, the days-to-cover ratio is presently 0.1 days.
View Anchiano Therapeutics' Short Interest.

Who are some of Anchiano Therapeutics' key competitors?

Some companies that are related to Anchiano Therapeutics include Assertio (ASRT), CV Sciences (CVSI), Vaccinex (VCNX), Zomedica (ZOM), Innovate Biopharmaceuticals (INNT), Pulmatrix (PULM), Cumberland Pharmaceuticals (CPIX), PDS Biotechnology (PDSB), Aileron Therapeutics (ALRN), Addex Therapeutics (ADDXF), Sernova (SEOVF), Predictive Technology Group (PRED), Immuron (IMRN), PainReform (PRFX) and Ceapro (CRPOF).
View all competitors.

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Aurora Cannabis (ACB), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).

Who are Anchiano Therapeutics' key executives?

Anchiano Therapeutics' management team includes the following people:

Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 54, Pay $352k)
Mr. Neil H. Cohen, CEO & Director (Age 57)
Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 82)
Mr. Andrew Fine, Chief Financial Officer (Age 50)
Mr. Salar Roshan, VP & Head of Bus. Devel. (Age 37)
Mr. Avraham Hampel M.B.A., Deputy CFO & Company Sec.
Mr. Or Dolev, Controller (Age 42)

When did Anchiano Therapeutics IPO?

(ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Anchiano Therapeutics' stock symbol?

Anchiano Therapeutics trades on the NASDAQ under the ticker symbol "ANCN."

How do I buy shares of Anchiano Therapeutics?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anchiano Therapeutics' stock price today?

One share of ANCN stock can currently be purchased for approximately $1.57.

How big of a company is Anchiano Therapeutics?

Anchiano Therapeutics has a market capitalization of $11.65 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Anchiano Therapeutics employs 16 workers across the globe.

What is Anchiano Therapeutics' official website?

The official website for Anchiano Therapeutics is www.anchiano.com.

How can I contact Anchiano Therapeutics?

Anchiano Therapeutics' mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings